Report Adverse Event or Product Quality Complaint    US Site     Global Site

AZmedical Information Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
    • Oncology Pipeline Tool
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ESMO 2026

European Society for Medical Oncology

October 23–27, 2026

  1. All
  2. Datopotamab deruxtecan
  3. Durvalumab/Datopotamab deruxtecan
  4. osimertinib
  5. Trastuzumab deruxtecan
  6. Capivasertib
  7. Camizestrant
  8. Puxitatug samrotecan
  9. Olaparib/durvalumab
  10. Torvutatug samrotecan
  11. Rilvegostomig
  12. Durvalumab
  13. Olaparib
  14. Saruparib
  15. AZD2265
  16. Durvalumab ± Tremelimumab
  17. Osimertinib + savolitinib
  18. Durvalumab/Tremelimumab
  19. Durvalumab/Olaparib
  20. Sonesitatug vedotin
  21. AZD7003

PDF

Mechanisms of insensitivity to the datopotamab deruxtecan (Dato-DXd) payload in subgroups of patients with advanced non-small cell lung cancer (NSCLC) in TROPION Lung01

PDF

TROPION-SWISH: Prophylaxis for datopotamab deruxtecan (Dato-DXd) related oral mucositis/stomatitis in patients (pts) with metastatic or inoperable locally recurrent breast cancer (BC) or locally advanced/metastatic EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)

PPT

NeoCOAST-2: Association of ctDNA clearance with clinical outcomes in a global platform Phase 2 perioperative trial

PDF

Real-world (rw) clinical outcomes with second-line (2L) osimertinib (osi) + platinum-based chemotherapy (CTx) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC and progression on first-line (1L) osi

PDF

Osimertinib (osi) rechallenge after interstitial lung disease (ILD) during osi treatment (tx) in EGFR-mutated advanced non-small cell lung cancer (NSCLC): A retrospective chart review study

PDF

FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed (plat-pem)

PDF

First-line (1L) trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutant (HER2m) NSCLC: patient-reported outcomes (PROs) from DESTINY-Lung04 (DL-04)

PDF

Capivasertib + fulvestrant for patients (pts) with hormone receptor-positive (HR+) advanced breast cancer (ABC): Management of common adverse events (AEs) from the Phase III CAPItello-291 trial

PDF

Modelling the economic impact of ESR1 monitoring in HR+/HER2− metastatic breast patients

PDF

Cross-country variation in real-world treatment patterns and outcomes for HR+/HER2− metastatic breast cancer in Europe: a multi-country study (DREAM-EU)

PDF

Treatment patterns and durability across lines of therapy in patients with HR+/HER2− metastatic breast cancer: results from a multi-country European real-world study (DREAM-EU)

PDF

First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Exploratory analysis of pts with brain metastases in TROPION-Breast02.

PDF

Prevalence of B7-H4 expression in commercially available endometrial cancer (EC) tumour samples

PDF

In vivo study on heterogeneous model system demonstrates specific Puxitatug samrotecan activity and suggests bystander activity

PDF

Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): interim overall survival (OS) and safety from the randomised Phase 3 DUO-E/GOG-3041/ENGOT-EN10 study

PDF

Updated results from FONTANA: Torvutatug samrotecan (torvu-sam), a folate receptor α (FRα)-targeted antibody-drug conjugate (ADC), in patients (pts) with platinum-resistant ovarian cancer (PROC)

PDF

A Phase 1b/2 platform study evaluating rilvegostomig in combination with CT, with or without ramucirumab, in pts with advanced or metastatic NSCLC

PDF

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): primary analysis of the phase 3 DeLLphi-305 trial

PDF

Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study

PDF

Zakharia Y, Powles T, Van der Heijden MS et al. Outcomes in Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC) With Divergent Differentiation or Histologic Subtypes (DDHS) From NIAGARA [Poster]. Presented at: European Society For Medical Oncology (ESMO) congress; 23-27 October 2026; Madrid Spain. Poster 4764P.

PDF

Clarke N, Barnicle A, Harrington EA, et al. Detection of homologous recombination deficiency (HRD) using a prostate cancer-specific genomic instability score (PrGIS) in patients with metastatic castration-resistant prostate cancer (mCRPC) in the Phase III PROpel trial [Poster]. Presented at: European Society For Medical Oncology (ESMO) congress; 23-27 October 2026; Madrid Spain. Poster 2257P.

PDF

Hudson A, Voskoboynik M, Weickhardt A, et al. Phase 1/2 PETRANHA trial: Saruparib + apalutamide + androgen deprivation therapy (ADT) in patients (pts) with metastatic prostate cancer (PC) [ePoster]. Presented at: European Society For Medical Oncology (ESMO) congress; 23-27 October 2026; Madrid Spain. ePoster 2322eP

PDF

Morris MJ, Sartor O, Matsubara N, et al. VECTRA-01: A Phase III study of actinium (225Ac) zadavotide guraxetan (Zada-Gu; AZD2265) versus standard of care (SoC) in pretreated patients (pts) with PSMA-positive (PSMA+) metastatic castration-resistant prostate cancer (mCRPC).Presented at: European Society For Medical Oncology (ESMO) congress; 23-27 October 2026; Madrid Spain. ePoster 2389eTiP

PDF

Galsky M, van der Heijden M, Joshi R, et al. Exploratory Analysis of Molecular Subtypes and Association With Treatment Outcomes in Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC) From NIAGARA [Rapid Oral]. Presented at: European Society For Medical Oncology (ESMO) congress; 23-27 October 2026; Madrid Spain. 4741RO.

PDF

De Santis M, Shore ND, Redorta JP, et al. Durvalumab (D) in Combination With BCG Induction and Maintenance (I+M) for BCG-Naïve, High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): Early Recurrence and Cystectomy-Free Survival in Patients (pts) With Papillary Only Tumours From POTOMAC [Rapid oral]. Presented at: European Society For Medical Oncology (ESMO) congress; 23-27 October 2026; Madrid Spain. Rapid oral 4737RO

PDF

Powles T, Grande E, Simone G, et al. Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: results from the Phase 3 VOLGA trial [oral]. Presented at: European Society For Medical Oncology (ESMO) congress; 23-27 October 2026; Madrid Spain. LBA2

PDF

Fizazi et al. Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone sensitive prostate cancer (mHSPC): updated overall survival (OS) from CAPItello-281 [Rapid oral]. Presented at: European Society For Medical Oncology (ESMO) congress; 23-27 October 2026; Madrid Spain. LBA56.

PPT

Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) advanced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results

PPT

Savolitinib or Placebo Combined with Osimertinib in Treatment-Naïve Advanced NSCLC with EGFR Mutation and MET Overexpression: Results from the Phase 3 SANOVO Study

PDF

A DESTINY-Breast09  analysis of trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC) and baseline (BL) brain metastases (BMs)

PDF

Trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in HR+, HER2-low metastatic breast cancer: a DESTINY-Breast06 ctDNA molecular response analysis

PDF

DESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in HER2+ early breast cancer (eBC)

PDF

Patient-reported outcomes (PROs) from DESTINY-Breast05: health-related quality of life (HRQoL) with trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with high-risk HER2-positive early breast cancer (eBC)

PDF

Trastuzumab deruxtecan (T-DXd) + pembrolizumab (PEM) in previously treated human epidermal growth factor receptor 2 (HER2)-expressing advanced or metastatic breast cancer (mBC): primary analyses of the breast cohorts from the open-label, multicenter, phase 1b study DS8201-A-U106.

PDF

A global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)-based therapy followed by palbociclib, endocrine therapy (ET), and dual HER2 blockade in first-line (1L) human epidermal growth factor receptor 2-positive (HER2+), hormone receptor-positive (HR+) advanced or metastatic breast cancer (mBC) and retreatment with T-DXd (DESTINY-Breast Guide).

PDF

Association of baseline neutrophil-to-lymphocyte ratio with response to perioperative durvalumab in patients with resectable NSCLC from the phase 3 AEGEAN trial

PDF

MDT-BRIDGE ctDNA

PDF

Global quantitative chart review of multidisciplinary team care and treatment in patients with stage I–II, unresected non-small-cell lung cancer

PDF

Real-world treatment patterns and outcomes in patients with unresected stage I–II non-small-cell lung cancer: The TERESA study

PDF

Seven-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in first-line (1L) unresectable hepatocellular carcinoma (uHCC)

PPT

Liver function trajectory and post-progression outcomes in the Phase 3 EMERALD-3 study of tremelimumab (T) + durvalumab (D) ± lenvatinib (L) + transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible hepatocellular carcinoma (eeHCC)

HTML

Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme)

HTML

OPTIMUM: A randomized phase 2 study of maintenance olaparib (Ola) with or without durvalumab (Durva) in DDR gene-mutated advanced biliary tract cancer (aBTC)

PDF

Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) vs ramucirumab plus paclitaxel in second-line treatment of patients with HER2+ unresectable/metastatic gastric cancer /gastroesophageal junction adenocarcinoma from DESTINY-Gastric04

PDF

Impact of prior immune checkpoint inhibitor (ICI) treatments on the clinical outcomes of trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in human epidermal growth factor receptor 2-positive (HER2+) advanced gastric cancer (GC)/ gastroesophageal junction adenocarcinoma (GEJA): exploratory analysis from DESTINY-Gastric04

PDF

Perioperative trastuzumab deruxtecan plus capecitabine and durvalumab in HER2-positive gastric or gastroesophageal junction cancer: a phase II study (EPOC2003)

PDF

ESPERANZA: Results from an External Comparator Study of Trastuzumab Deruxtecan in HER2 IHC3+ Solid Tumors

PDF

HER2 expression by IHC across multiple solid tumor types: insights from the ESPERANZA study programme

PPT

CLARITY-Gastric01 (CG-01): A Phase 3 study of sonesitatug vedotin (Sone-Ve) in second or later-line (2L+) advanced or metastatic Claudin18.2 (CLDN18.2) positive gastroesophageal carcinoma (GEC)

PDF

CLARITY-Gastric02: a randomised Phase 3 study of sonesitatug vedotin (Sone-Ve) and capecitabine with or without rilvegostomig in Claudin18.2 positive (CLDN18.2+) advanced or metastatic gastric, gastroesophageal junction, or oesophageal adenocarcinoma (GC / GEJC / EAC)

PDF

In vivo study on heterogeneous model system demonstrates specific Puxitatug samrotecan activity and suggests bystander activity

PDF

PARTHENON: A phase I/IIa study of AZD4956, a DNA polymerase theta (POLQ) inhibitor, as monotherapy or in combination with saruparib in patients with homologous recombination repair (HRR) deficient advanced/metastatic solid tumours

PDF

Staging accuracy and survival of resectable gastric adenocarcinoma: A retrospective study of Taiwanese patients

PDF

Resectable gastric and gastroesophageal junction cancer in France: Real-world perioperative FLOT outcomes from the FREGAT database.

PDF

Economic burden of resectable gastroesophageal adenocarcinomas: A population-based study in Denmark

PPT

Phase I study of C-CAR031, a GPC3-targeted TGFβRIIDN armored autologous CAR-T, in advanced hepatocellular carcinoma (aHCC): Updated Results

PDF

Mechanisms of insensitivity to the datopotamab deruxtecan (Dato-DXd) payload in subgroups of patients with advanced non-small cell lung cancer (NSCLC) in TROPION Lung01

PDF

TROPION-SWISH: Prophylaxis for datopotamab deruxtecan (Dato-DXd) related oral mucositis/stomatitis in patients (pts) with metastatic or inoperable locally recurrent breast cancer (BC) or locally advanced/metastatic EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)

PDF

First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Exploratory analysis of pts with brain metastases in TROPION-Breast02.

PPT

NeoCOAST-2: Association of ctDNA clearance with clinical outcomes in a global platform Phase 2 perioperative trial

PDF

Real-world (rw) clinical outcomes with second-line (2L) osimertinib (osi) + platinum-based chemotherapy (CTx) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC and progression on first-line (1L) osi

PDF

Osimertinib (osi) rechallenge after interstitial lung disease (ILD) during osi treatment (tx) in EGFR-mutated advanced non-small cell lung cancer (NSCLC): A retrospective chart review study

PDF

FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed (plat-pem)

PDF

First-line (1L) trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutant (HER2m) NSCLC: patient-reported outcomes (PROs) from DESTINY-Lung04 (DL-04)

PDF

A DESTINY-Breast09  analysis of trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC) and baseline (BL) brain metastases (BMs)

PDF

Trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in HR+, HER2-low metastatic breast cancer: a DESTINY-Breast06 ctDNA molecular response analysis

PDF

DESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in HER2+ early breast cancer (eBC)

PDF

Patient-reported outcomes (PROs) from DESTINY-Breast05: health-related quality of life (HRQoL) with trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with high-risk HER2-positive early breast cancer (eBC)

PDF

Trastuzumab deruxtecan (T-DXd) + pembrolizumab (PEM) in previously treated human epidermal growth factor receptor 2 (HER2)-expressing advanced or metastatic breast cancer (mBC): primary analyses of the breast cohorts from the open-label, multicenter, phase 1b study DS8201-A-U106.

PDF

A global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)-based therapy followed by palbociclib, endocrine therapy (ET), and dual HER2 blockade in first-line (1L) human epidermal growth factor receptor 2-positive (HER2+), hormone receptor-positive (HR+) advanced or metastatic breast cancer (mBC) and retreatment with T-DXd (DESTINY-Breast Guide).

PDF

Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) vs ramucirumab plus paclitaxel in second-line treatment of patients with HER2+ unresectable/metastatic gastric cancer /gastroesophageal junction adenocarcinoma from DESTINY-Gastric04

PDF

Impact of prior immune checkpoint inhibitor (ICI) treatments on the clinical outcomes of trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in human epidermal growth factor receptor 2-positive (HER2+) advanced gastric cancer (GC)/ gastroesophageal junction adenocarcinoma (GEJA): exploratory analysis from DESTINY-Gastric04

PDF

Perioperative trastuzumab deruxtecan plus capecitabine and durvalumab in HER2-positive gastric or gastroesophageal junction cancer: a phase II study (EPOC2003)

PDF

ESPERANZA: Results from an External Comparator Study of Trastuzumab Deruxtecan in HER2 IHC3+ Solid Tumors

PDF

HER2 expression by IHC across multiple solid tumor types: insights from the ESPERANZA study programme

PDF

Capivasertib + fulvestrant for patients (pts) with hormone receptor-positive (HR+) advanced breast cancer (ABC): Management of common adverse events (AEs) from the Phase III CAPItello-291 trial

PDF

Fizazi et al. Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone sensitive prostate cancer (mHSPC): updated overall survival (OS) from CAPItello-281 [Rapid oral]. Presented at: European Society For Medical Oncology (ESMO) congress; 23-27 October 2026; Madrid Spain. LBA56.

PDF

Modelling the economic impact of ESR1 monitoring in HR+/HER2− metastatic breast patients

PDF

Cross-country variation in real-world treatment patterns and outcomes for HR+/HER2− metastatic breast cancer in Europe: a multi-country study (DREAM-EU)

PDF

Treatment patterns and durability across lines of therapy in patients with HR+/HER2− metastatic breast cancer: results from a multi-country European real-world study (DREAM-EU)

PDF

Prevalence of B7-H4 expression in commercially available endometrial cancer (EC) tumour samples

PDF

In vivo study on heterogeneous model system demonstrates specific Puxitatug samrotecan activity and suggests bystander activity

PDF

In vivo study on heterogeneous model system demonstrates specific Puxitatug samrotecan activity and suggests bystander activity

PDF

Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): interim overall survival (OS) and safety from the randomised Phase 3 DUO-E/GOG-3041/ENGOT-EN10 study

PDF

Updated results from FONTANA: Torvutatug samrotecan (torvu-sam), a folate receptor α (FRα)-targeted antibody-drug conjugate (ADC), in patients (pts) with platinum-resistant ovarian cancer (PROC)

PDF

A Phase 1b/2 platform study evaluating rilvegostomig in combination with CT, with or without ramucirumab, in pts with advanced or metastatic NSCLC

PDF

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): primary analysis of the phase 3 DeLLphi-305 trial

PDF

Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study

PDF

Zakharia Y, Powles T, Van der Heijden MS et al. Outcomes in Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC) With Divergent Differentiation or Histologic Subtypes (DDHS) From NIAGARA [Poster]. Presented at: European Society For Medical Oncology (ESMO) congress; 23-27 October 2026; Madrid Spain. Poster 4764P.

PDF

Galsky M, van der Heijden M, Joshi R, et al. Exploratory Analysis of Molecular Subtypes and Association With Treatment Outcomes in Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC) From NIAGARA [Rapid Oral]. Presented at: European Society For Medical Oncology (ESMO) congress; 23-27 October 2026; Madrid Spain. 4741RO.

PDF

De Santis M, Shore ND, Redorta JP, et al. Durvalumab (D) in Combination With BCG Induction and Maintenance (I+M) for BCG-Naïve, High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): Early Recurrence and Cystectomy-Free Survival in Patients (pts) With Papillary Only Tumours From POTOMAC [Rapid oral]. Presented at: European Society For Medical Oncology (ESMO) congress; 23-27 October 2026; Madrid Spain. Rapid oral 4737RO

PDF

Association of baseline neutrophil-to-lymphocyte ratio with response to perioperative durvalumab in patients with resectable NSCLC from the phase 3 AEGEAN trial

PDF

MDT-BRIDGE ctDNA

PDF

Global quantitative chart review of multidisciplinary team care and treatment in patients with stage I–II, unresected non-small-cell lung cancer

PDF

Real-world treatment patterns and outcomes in patients with unresected stage I–II non-small-cell lung cancer: The TERESA study

PDF

Staging accuracy and survival of resectable gastric adenocarcinoma: A retrospective study of Taiwanese patients

PDF

Resectable gastric and gastroesophageal junction cancer in France: Real-world perioperative FLOT outcomes from the FREGAT database.

PDF

Economic burden of resectable gastroesophageal adenocarcinomas: A population-based study in Denmark

PDF

Clarke N, Barnicle A, Harrington EA, et al. Detection of homologous recombination deficiency (HRD) using a prostate cancer-specific genomic instability score (PrGIS) in patients with metastatic castration-resistant prostate cancer (mCRPC) in the Phase III PROpel trial [Poster]. Presented at: European Society For Medical Oncology (ESMO) congress; 23-27 October 2026; Madrid Spain. Poster 2257P.

PDF

Hudson A, Voskoboynik M, Weickhardt A, et al. Phase 1/2 PETRANHA trial: Saruparib + apalutamide + androgen deprivation therapy (ADT) in patients (pts) with metastatic prostate cancer (PC) [ePoster]. Presented at: European Society For Medical Oncology (ESMO) congress; 23-27 October 2026; Madrid Spain. ePoster 2322eP

PDF

PARTHENON: A phase I/IIa study of AZD4956, a DNA polymerase theta (POLQ) inhibitor, as monotherapy or in combination with saruparib in patients with homologous recombination repair (HRR) deficient advanced/metastatic solid tumours

PDF

Morris MJ, Sartor O, Matsubara N, et al. VECTRA-01: A Phase III study of actinium (225Ac) zadavotide guraxetan (Zada-Gu; AZD2265) versus standard of care (SoC) in pretreated patients (pts) with PSMA-positive (PSMA+) metastatic castration-resistant prostate cancer (mCRPC).Presented at: European Society For Medical Oncology (ESMO) congress; 23-27 October 2026; Madrid Spain. ePoster 2389eTiP

PDF

Powles T, Grande E, Simone G, et al. Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: results from the Phase 3 VOLGA trial [oral]. Presented at: European Society For Medical Oncology (ESMO) congress; 23-27 October 2026; Madrid Spain. LBA2

PPT

Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) advanced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results

PPT

Savolitinib or Placebo Combined with Osimertinib in Treatment-Naïve Advanced NSCLC with EGFR Mutation and MET Overexpression: Results from the Phase 3 SANOVO Study

PDF

Seven-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in first-line (1L) unresectable hepatocellular carcinoma (uHCC)

PPT

Liver function trajectory and post-progression outcomes in the Phase 3 EMERALD-3 study of tremelimumab (T) + durvalumab (D) ± lenvatinib (L) + transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible hepatocellular carcinoma (eeHCC)

HTML

Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme)

HTML

OPTIMUM: A randomized phase 2 study of maintenance olaparib (Ola) with or without durvalumab (Durva) in DDR gene-mutated advanced biliary tract cancer (aBTC)

PPT

CLARITY-Gastric01 (CG-01): A Phase 3 study of sonesitatug vedotin (Sone-Ve) in second or later-line (2L+) advanced or metastatic Claudin18.2 (CLDN18.2) positive gastroesophageal carcinoma (GEC)

PDF

CLARITY-Gastric02: a randomised Phase 3 study of sonesitatug vedotin (Sone-Ve) and capecitabine with or without rilvegostomig in Claudin18.2 positive (CLDN18.2+) advanced or metastatic gastric, gastroesophageal junction, or oesophageal adenocarcinoma (GC / GEJC / EAC)

PPT

Phase I study of C-CAR031, a GPC3-targeted TGFβRIIDN armored autologous CAR-T, in advanced hepatocellular carcinoma (aHCC): Updated Results

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Other Countries

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States